Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04228302 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, and Pharmacokinetics of Oral EC5026 in Healthy Subjects
A Phase 1 study of Healthy Adults, sponsored by EicOsis Human Health.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT04228302 is a Phase 1 study of Healthy Adults that has completed, run by EicOsis Human Health. The registered enrollment target is 40 participants, below the 85-participant average among 33 other Healthy Adults trials with a reported enrollment target (53% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04228302, a Phase 1 study of Healthy Adults, has completed, sponsored by EicOsis Human Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a first-in-human study with EC5026, a new drug candidate intended to treat neuropathic pain. The purpose of the study is to provide initial safety, tolerability, and pharmacokinetics data of single ascending oral doses of EC5026 in healthy subjects.
Conditions Studied
Interventions
- DRUG EC5026 oral capsule
- OTHER Placebo oral capsule
Study Locations (1)
Texas
- PPD Phase I Clinic - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2019-12-09 |
| Est. Completion | 2020-07-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04228302
The ClinicalTrials.gov registry entry for NCT04228302 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 85-participant average among 33 other Healthy Adults trials with a reported enrollment target (53% lower). The listed sponsor is EicOsis Human Health, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Adults appearing as the primary indexed condition, and to 2 interventions - of which EC5026 oral capsule is the first listed.
NCT04228302 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT04228302 about?
NCT04228302 is a clinical study titled "Safety, Tolerability, and Pharmacokinetics of Oral EC5026 in Healthy Subjects". This is a first-in-human study with EC5026, a new drug candidate intended to treat neuropathic pain. The purpose of the study is to provide initial safety, tolerability, and pharmacokinetics data of single ascending oral doses of EC5026 in healthy subjects.
What is the current status of trial NCT04228302?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2019-12-09. Estimated completion is 2020-07-07.
What conditions does trial NCT04228302 study?
This clinical trial studies the following conditions: Healthy Adults.
What interventions are being tested in trial NCT04228302?
The interventions under investigation include: EC5026 oral capsule (DRUG), Placebo oral capsule (OTHER).
Who is sponsoring clinical trial NCT04228302?
This trial is sponsored by EicOsis Human Health, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04228302 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Adults
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of EDG-15400 in Healthy Adults
RECRUITING · Phase 1
-
A Study to Learn About How the Study Medicines Called Itraconazole and Probenecid Change How the Body Processes PF-07220060
RECRUITING · Phase 1
-
Phase 1a Single Ascending Dose Study of MIB-725 in Healthy Adults
RECRUITING · Phase 1
-
Safety and Efficacy of Injectable Klotho Plasmid Gene Therapy in Humans
RECRUITING · Phase 1
-
Tracing the Metabolic Flux of Orally Administered NAD+ Precursors
RECRUITING · Phase 1
-
The Dose Response of Prednisone on Biochemical and Clinical Makers in Adult Healthy Volunteers
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.